ES2970546T3 - Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño - Google Patents

Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño Download PDF

Info

Publication number
ES2970546T3
ES2970546T3 ES17865155T ES17865155T ES2970546T3 ES 2970546 T3 ES2970546 T3 ES 2970546T3 ES 17865155 T ES17865155 T ES 17865155T ES 17865155 T ES17865155 T ES 17865155T ES 2970546 T3 ES2970546 T3 ES 2970546T3
Authority
ES
Spain
Prior art keywords
benzimidazol
ethyl
methoxy
ethoxy
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17865155T
Other languages
English (en)
Spanish (es)
Inventor
Werneck Guimarães Cristiano Ruch
Zaneti De Azevedo Hatylas Felype
Alessandra Mascarello
Da Costa Renata Watanabe
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Application granted granted Critical
Publication of ES2970546T3 publication Critical patent/ES2970546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17865155T 2016-10-24 2017-10-23 Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño Active ES2970546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (1)

Publication Number Publication Date
ES2970546T3 true ES2970546T3 (es) 2024-05-29

Family

ID=62023150

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17865155T Active ES2970546T3 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño
ES20185268T Active ES3013994T3 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20185268T Active ES3013994T3 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Country Status (20)

Country Link
US (2) US10781182B2 (cg-RX-API-DMAC7.html)
EP (2) EP3529234B1 (cg-RX-API-DMAC7.html)
JP (1) JP7194683B2 (cg-RX-API-DMAC7.html)
KR (1) KR102594251B1 (cg-RX-API-DMAC7.html)
CN (2) CN110088092B (cg-RX-API-DMAC7.html)
AR (1) AR109467A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017351756B2 (cg-RX-API-DMAC7.html)
BR (1) BR102016024814A2 (cg-RX-API-DMAC7.html)
CL (1) CL2019001105A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004756A2 (cg-RX-API-DMAC7.html)
DK (1) DK3529234T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19032963A (cg-RX-API-DMAC7.html)
ES (2) ES2970546T3 (cg-RX-API-DMAC7.html)
FI (1) FI3529234T3 (cg-RX-API-DMAC7.html)
MX (1) MX392990B (cg-RX-API-DMAC7.html)
PE (2) PE20250558A1 (cg-RX-API-DMAC7.html)
PT (1) PT3529234T (cg-RX-API-DMAC7.html)
SG (2) SG11201903113TA (cg-RX-API-DMAC7.html)
UY (2) UY40644A (cg-RX-API-DMAC7.html)
WO (1) WO2018076090A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
EP3433256B1 (en) 2016-10-24 2019-08-07 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer
CR20190379A (es) 2017-01-30 2019-10-21 Astrazeneca Ab Moduladores del receptor de estrógeno
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
CA3179907A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
BR112022021089A2 (pt) 2020-04-24 2022-12-06 Astrazeneca Ab Formulações farmacêuticas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
DE69528843T2 (de) * 1994-06-10 2003-09-18 Naucno-Issledovatel'skij Institut Farmakologii Akademii Medicinskich Nauk Sssr, Moskau/Moskva Pharmakologisch aktive 2-mercaptobenzimidazolderivate
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
AU719994B2 (en) 1996-12-10 2000-05-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
WO1999062515A1 (en) 1998-06-05 1999-12-09 Bristol-Myers Squibb Company Heterocyclic cis cyclopropane derivatives as melatonergic agents
CA2376949C (en) 1999-06-30 2009-05-26 Katherine S. Takaki Heterocyclic aminopyrrolidine derivatives as melatonergic agents
WO2003062224A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP1719761A4 (en) 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
US20090298811A1 (en) * 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
EP2088861A4 (en) * 2006-10-25 2010-07-07 Takeda Pharmaceutical Benzimidazole compounds
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Also Published As

Publication number Publication date
EP3741760C0 (en) 2024-12-04
CN110088092A (zh) 2019-08-02
PE20191046A1 (es) 2019-08-06
BR102016024814A2 (pt) 2018-05-08
MX392990B (es) 2025-03-24
PT3529234T (pt) 2024-02-01
SG10202009001TA (en) 2020-10-29
CN115181108A (zh) 2022-10-14
CO2019004756A2 (es) 2019-05-21
CA3042040A1 (en) 2018-05-03
DK3529234T3 (da) 2024-02-05
UY40644A (es) 2024-02-29
ECSP19032963A (es) 2019-05-31
EP3741760B1 (en) 2024-12-04
US10781182B2 (en) 2020-09-22
EP3529234A1 (en) 2019-08-28
EP3529234B1 (en) 2023-11-29
AU2017351756B2 (en) 2022-01-27
FI3529234T3 (fi) 2023-12-28
CL2019001105A1 (es) 2019-09-06
EP3741760A1 (en) 2020-11-25
AR109467A1 (es) 2018-12-12
MX2019004782A (es) 2019-10-09
EP3529234A4 (en) 2020-03-11
KR102594251B1 (ko) 2023-10-25
WO2018076090A1 (en) 2018-05-03
ES3013994T3 (en) 2025-04-16
AU2017351756A1 (en) 2019-05-09
BR112019008197A2 (pt) 2019-07-16
SG11201903113TA (en) 2019-05-30
US20200277265A1 (en) 2020-09-03
PE20250558A1 (es) 2025-02-24
US11091445B2 (en) 2021-08-17
US20190270711A1 (en) 2019-09-05
KR20190066023A (ko) 2019-06-12
UY37334A (es) 2018-04-30
JP7194683B2 (ja) 2022-12-22
CN110088092B (zh) 2022-10-04
JP2019537624A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
ES2970546T3 (es) Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño
ES2886361T3 (es) Uso de (2R,6R)-hidroxinorketamina y otros metabolitos hidroxilados estereoisómeros de (R,S)-ketamina en el tratamiento de depresión y dolor neuropático
JP2025069411A (ja) 脳障害を治療するためのn-置換インドール及び他の複素環化合物
EP3196197A1 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
CA3017388A1 (en) Estrogen receptor modulators
BR112015001545B1 (pt) Composto, composição farmacêutica, e, uso de um composto
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
JP2025511343A (ja) N-置換キノリノン化合物、その製造方法及びその使用
CA3042040C (en) 2-substituted benzimidazolyl compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
ES2271673T3 (es) Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
KR20070087644A (ko) 도파민-d2 수용체 및 세로토닌 재흡수 위치에 대한친화도를 함께 갖는 벤즈디옥산 피페라진 유도체
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
JP2021522196A (ja) 血液脳関門を越えて送達するためのアセチル化プロドラッグ
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
WO2024124050A1 (en) Multicyclic compounds
WO2024124043A1 (en) Multicyclic compounds
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
CN120230029A (zh) 整合素α4β7拮抗剂化合物及其制备方法与应用
CN116693470A (zh) 组胺h3受体抑制剂及其医药用途
HK1131976A (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them